Tack Véronique, Deans Zandra C, Wolstenholme Nicola, Patton Simon, Dequeker Elisabeth M C
Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, KU Leuven, Leuven, Belgium.
Department of Laboratory Medicine, UK NEQAS for Molecular Genetics, UK NEQAS Edinburgh, The Royal Infirmary of Edinburgh, Edinburgh, UK.
Hum Mutat. 2016 Jun;37(6):570-5. doi: 10.1002/humu.22975. Epub 2016 Mar 14.
The Human Genome Variation Society (HGVS) recommendations provide standardized nomenclature for reporting variants. This should be encouraged in molecular pathology-both for issuing diagnostic reports and for correct data recording in electronic databases. Many providers of external quality assessment (EQA) promote the correct use of HGVS nomenclature by scoring variant descriptions used in EQA reports. This study focuses on the type and impact of variant nomenclature errors. An assessment was made of EGFR gene variant nomenclature by four EQA providers (European Society of Pathology [ESP], European Molecular Genetics Quality Network [EMQN], United Kingdom National External Quality Assessment Service for Molecular Genetics, and the French national Gen&Tiss EQA scheme) for two EQA distributions. Laboratories testing for oncology biomarkers make different errors when describing EGFR gene variants. Significant differences were observed regarding inclusion of the correct reference sequence: EMQN participants made fewer errors compared to ESP EQA participants (P-value = 0.015). The analysis of ESP EQA participants showed significant improvement over 2 years (P-value = 0.016). Results demonstrate the need for improvement of variant reporting according to HGVS guidelines. Consequences of using incorrect mutation nomenclature are currently perceived as low by many laboratories, but the impact will rise with an increased reliance on databases to assist in result analysis.
人类基因组变异协会(HGVS)的建议为报告变异提供了标准化命名法。在分子病理学中,无论是出具诊断报告还是在电子数据库中正确记录数据,都应鼓励使用这种命名法。许多外部质量评估(EQA)提供者通过对EQA报告中使用的变异描述进行评分,来促进HGVS命名法的正确使用。本研究聚焦于变异命名错误的类型及其影响。四家EQA提供者(欧洲病理学会[ESP]、欧洲分子遗传学质量网络[EMQN]、英国国家分子遗传学外部质量评估服务机构以及法国国家Gen&Tiss EQA计划)针对两次EQA分发对EGFR基因变异命名法进行了评估。检测肿瘤生物标志物的实验室在描述EGFR基因变异时会出现不同的错误。在纳入正确参考序列方面观察到显著差异:与ESP EQA参与者相比,EMQN参与者的错误较少(P值 = 0.015)。对ESP EQA参与者的分析显示,两年内有显著改善(P值 = 0.016)。结果表明需要根据HGVS指南改进变异报告。目前许多实验室认为使用错误的突变命名法的后果较小,但随着对数据库辅助结果分析的依赖增加,其影响将会上升。